The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a novel oral fumarate candidate, diroximel fumarate (Alkermes and Biogen), for the treatment of relapsing forms of multiple sclerosis (MS).
Diroximel fumarate is designed to rapidly convert to monomethyl fumarate in the body, the active metabolite of dimethyl fumarate (Tecfidera; Biogen). Due to its chemical properties, it has the potential for improved gastrointestinal (GI) tolerability when compared with dimethyl fumarate.
